Novel Treatments for Castration-Resistant Prostate Cancer

Please read this page carefully. You will need to scroll down this page and ensure that you have read the learning objectives, accreditation information, and potential conflicts of interest disclosures for the authoring faculty. Please check the box to agree to the terms of understanding and click the "Start Module" button on the bottom of the page to begin your learning activity.

Learning Objectives
After successful completion of this activity, participants will be able to:

  • Describe the mechanisms of newly approved and promising investigational agents for castration-resistant prostate cancer (CRPC), and review supporting data and ongoing clinical trials for these agents
  • Appropriately select and sequence both newly approved and standard therapies for all stages of CRPC (asymptomatic, chemo-naïve, docetaxel-resistant, etc.)
  • Monitor and manage treatment-related adverse effects and disease-induced bone effects
  • Apply best evidence-based practices and latest clinical guidelines to the management of CRPC.

This learning activity has been designated for 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credits commensurate with the extent of their participation in this activity.

Target Audience
This educational activity is specifically designed for medical oncologists, urologists, and other physicians, clinicians, physicians-in-training, and health-care professionals (oncology nurses, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with castration-resistant prostate cancer.

Release date: September 4, 2013
Expiration date: September 4, 2014

The following companies have provided unrestricted educational grants in support of this activity: Exelixis, Inc. and Teva Pharmaceuticals.

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), Imedex, LLC must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Faculty are encouraged to provide a balanced view of therapeutic options by utilizing generic names of several to ensure impartiality.

All faculty participating in an Imedex activity are required to disclose commitments to and/or relationships with pharmaceutical companies, biomedical device manufacturers or distributors, or others whose products or services may be considered to be related to the subject matter of the educational activity. Disclosure of these commitments and/or relationships is included in these course materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.

The following indicates the faculty disclosure declaration information and the nature of those commercial relationships.

1=grant/research support; 2=consultant; 3=speaker's bureau; 4=stock shareholder; 5=other support

Charles Ryan, MD: Astellas Pharma Inc.2; Dendreon5; GTx, Inc.2; Janssen Pharmaceuticals5

All materials are included with the permission of the authors.

Imedex, LLC Staff Disclosure of Financial Relationships
Imedex, LLC is a subsidiary of AmerisourceBergen Company. All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline and AmerisourceBergen Company.

Bradley Bongiovanni ND owns shares of stock of AmerisourceBergen Company.

Disclosure of Unapproved Uses and Investigational Drugs
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the US Food and Drug Administration (FDA) and/or other national regulatory agencies in the United States and other countries. Participants in the United States are encouraged to consult the FDA-approved product labeling for any drug or device mentioned in this program before use. Participants from other countries should consult with their respective regulatory authorities.

The opinions expressed in this webcast are the opinions of the authors and do not necessarily reflect the opinions of Imedex.

Click here to view Technical Requirements

Click here to view How To Complete a Learning Module and Claim Credits

(*Please check this box to proceed - required)

Registration Required
To access CME activities and to view your personalized CME Profile page, which tracks completed learning modules, post-test scores and CME credits earned, and allows you to download printable CME certificates.

Send us your comments
We welcome your feedback and / or questions related to the educational content provided through this Website.
About Us Contact Us Terms of Use Privacy Policy Technical Requirements Site Map Help